Search results for "Phase IV"

showing 4 items of 4 documents

Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smok…

2007

Aims: To assess the role of smoking on treatment outcome in quitting alcoholics on the background of the priming or coping hypothesis (Rohsenow et al. , [1997][1]). Methods: Data sets of placebo treated patients of the German phase III trial of naltrexone (Gastpar et al. , [2002][2]) and of acamprosate treated patients of a German phase IV trial Soyka et al. , [2002][3]) were reanalyzed. Differences between smoking and non-smoking alcoholics were evaluated using χ2-, t - or ANOVA-tests, relapse rates using survival techniques with Cox regression. Results: Smoking alcoholics differed significantly from non-smoking alcoholics regarding sociodemographic variables (e.g. more males, more often l…

AdultMalemedicine.medical_specialtyCoping (psychology)TaurineAcamprosateNarcotic AntagonistsTemperanceComorbidityPlaceboPhase IV TrialSeverity of Illness IndexNaltrexonePharmacotherapySex FactorsRecurrenceInternal medicinemedicineOdds RatioHumansPsychiatryProportional Hazards Modelsbusiness.industryProportional hazards modelSmokingGeneral MedicineMiddle AgedNaltrexoneClinical trialAlcoholismAcamprosateTreatment OutcomeMultivariate AnalysisFemalebusinessmedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and…

2014

e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...

OncologySkin careCancer Researchmedicine.medical_specialtyCetuximabColorectal cancerbusiness.industrymedicine.diseaseRashPhase IV TrialSurgeryFirst line treatmentOncologyInternal medicinemedicineFOLFIRIOverall survivalmedicine.symptombusinessmedicine.drugJournal of Clinical Oncology
researchProduct

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutat…

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryAfatinibPhase IV TrialFirst line treatmentOncologyEgfr mutationInternal medicinemedicineOsimertinibIn patientbusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project.

2006

This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the 597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up per…

medicine.medical_specialtyNeurologyMultiple SclerosisDermatologySeverity of Illness IndexInterferon beta • Multiple sclerosis • Phase IV • Odds ratioInternal medicineSeverity of illnessmedicineConfidence IntervalsHumansImmunologic FactorsMultiple sclerosiNeuroradiologyAnalysis of Variancemedicine.diagnostic_testbusiness.industryMultiple sclerosisMagnetic resonance imagingGeneral MedicineOdds ratioInterferon-betaOdds ratiomedicine.diseaseInterferon betaMagnetic Resonance ImagingConfidence intervalPsychiatry and Mental healthItalyPhysical therapySettore MED/26 - NeurologiaNeurology (clinical)NeurosurgeryPhase IVbusinessFollow-Up Studies
researchProduct